

29th KWF Cancer Biology meeting 2022

Hotel 'de Werelt' Lunteren

Thursday November 24th, 2022

09.00 **Registration and coffee**

10.00 **Opening** Marcel Spaargaren, *Chair*

Session I: Cancer Biology I (4x)

Chairs: René Medema, Jan Jacob Schuringa

10.15 **Invasive Potential of Colorectal Cancer through Tumor Budding in 3D**

Tariq Haddad, *Radboud University Medical Center, Nijmegen*

10.30 **CD26-negative and CD26-positive tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in mouse models of breast cancer**

Julia M. Houthuijzen, *Onco Institute, Netherlands Cancer Institute, Amsterdam*

10.45 **Functional screens for microRNAs and their mRNA targets regulating anchorage-independent growth in human cervical cancer cells**

Angelina Huseinovic, *Amsterdam UMC (VU) and Cancer Center Amsterdam*

11.00 **Heparan sulfate proteoglycans regulate intestinal stemness and tumorigenesis**

Sander P.J. Joosten, *Amsterdam UMC (UvA) and Cancer Center Amsterdam*

11.15 **Coffee/Tea**

Session II: Cancer Biology II (5x)

Chairs: Annemiek van Spriel, Patrick Derksen

11.45 **Unraveling the malignant progression of diffuse gastric cancer by spatial transcriptomics**

Lars Kemp, *Center for Molecular Medicine, UMC Utrecht and Radboudumc Nijmegen*

12.00 **Mesenchymal CRCs are self-sustaining due to niche-mimicry (Nimicry)**

Kristiaan Lenos, *Amsterdam UMC (UvA) and Cancer Center Amsterdam*

12.15 **Tracing the origin of pediatric cancer using single-cell whole genome sequencing at unprecedented resolution**

Sjors Middelkamp, *Princess Máxima Center for Pediatric Oncology & Onco Institute, Utrecht*

12.30 **Systematic identification of silencers in the human genome**

Baoxu Pang, *Leiden University Medical Center*

12.45 **Aggressive luminal breast cancer identity is underpinned by loss of stress hormone receptor activity**

Stefan Prekovic, *Onco Institute, The Netherlands Cancer Institute, Amsterdam*

13.00 Lunch and poster pre-viewing (at 14.00 hr: meeting project leaders)

14.30 Invited lecture
How studies into hematopoietic stem cell aging reveal new molecules to target leukemia
Gerald de Haan, *Sanquin, Amsterdam*

Session III: Cancer Biology III (3x)

Chairs: Frank van Leeuwen, Susanne Lens

15.15 **On-treatment biopsies show that heterogeneous response to kinase inhibitor treatment has multiple distinct causes**
Bram Thijssen, *Netherlands Cancer Institute, Amsterdam, Oncode Institute, Utrecht University*

15.30 **Paneth cells as the origin of intestinal cancer in the context of inflammation**
Mathijs P. Verhagen, *Erasmus University Medical Center, Rotterdam*

15.45 **Proliferation-promoting roles of linear and circular PVT1 are independent of miRNA binding in B-cell Lymphoma**
Xing Zhao, *University Medical Center Groningen*

16.00 Coffee/Tea

Session IV: Target & Therapy Discovery I (5x)

Chairs: Linda Smit, Marc Vooijs

16.30 **What doesn't kill you makes your neighbour stronger: paracrine resistance to chemotherapy**

Florian Bock, *MAASTRO, GROW-School for Oncology and Developmental Biology, Maastricht University*

- 16.45 **The subcellular site of ROS generation determines cell fate**
Tobias Dansen, *Center for Molecular Medicine, UMC Utrecht*
- 17.00 **Evasion of tumor-suppressive FOXO activation in Multiple Myeloma through IGF1R and mTORC1 signaling**
Guus de Wilde, *Amsterdam UMC (UvA), LYMMCARE and Cancer Center Amsterdam*
- 17.15 **FER kinase governs invasive cancer growth through dynamic control of growth factor receptor activation**
Peter Haughton, *University Medical Center Utrecht*
- 17.30 **E-cadherin loss leads to Id2-dependent cell cycle inhibition in lobular breast cancer**
Thijs Koorman, *University Medical Center Utrecht*
- 17.45 **KWF presentation**
Lenno Krenning
- 18.00 **Dinner**
- 20.00 **Posters and Laptops**
- 22.00 **Disco** (sponsored by BIOKÉ) and drinks

Friday November 25th, 2022

Session V: Target & Therapy Discovery II (6x)

Chairs: Victor Peperzak, Przemek Krawczyk

09.00 **High-throughput drug screens identify EHMT2 inhibitors as potent thermo-sensitizers**

Enzo M. Scutigliani, Amsterdam University Medical Centers, UvA, Cancer Center Amsterdam

09.15 **Targeting histone methylation to reprogram the transcriptional state that drives survival of drug-tolerant myeloid leukemia persists**

Linda Smit, Amsterdam UMC (VU) and Cancer Center Amsterdam

09.30 **Inhibition of Casein Kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation**

Yvonne J. Thus, Amsterdam UMC (UvA), LYMMCARE and Cancer Center Amsterdam

09.45 **Replication stress promotes skin cancer development via the induction of a mitogenic secretory phenotype**

Anastasia Tsaalbi-Shtylik, Leiden University Medical Center

10.00 **Profile-guided low-dose drug combination strategies in pancreatic ductal adenocarcinoma: a phosphoproteomics approach**

Andrea Vallés-Martí, Amsterdam UMC (VU), Cancer Center Amsterdam

10.15 **Tyrosine kinase inhibitors sensitise triple-negative breast cancer cells to CDK12/13 inhibitor THZ531 by ABCG2 blockage**

Vera E. van der Noord, *Leiden University, Leiden Academic Centre for Drug Research*

10.30 **Coffee/Tea**

Session VI: Cancer Immunology (4x)

Chairs: Richarda de Voer, Wijnand Helfrich

11.00 **Targeting inducible aberrant neopeptides to boost anti-tumor immunity**

Julien Champagne, *Oncode institute, The Netherlands Cancer Institute, Amsterdam*

11.15 **Lymph node stromal cells have the toolbox to control anti-tumor immunity**

Lotte de Winde, *Amsterdam UMC (VU)*

11.30 **In Lynch syndrome microsatellite instability is common in a wide spectrum of malignancies**

Lisa Elze, *Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen*

11.45 **EGFR-directed blockade of the CD73-adenosine immune checkpoint**

Emily M. Ploeg, *University of Groningen, University, Medical Center Groningen*

12.00 **BIOKÉ presentation: What's new in cancer cell research**

Robbert Weren - *Field Application Scientist BIOKÉ*

- 12.15** Lunch
- 13.15** Invited Lecture
Linking LKB1 loss to intestinal epithelial reprogramming and cancer predisposition
Madelon Maurice, *Center for Molecular Medicine, UMC Utrecht*

Session VII: DNA damage & repair (2x)

Chair: Marcel van Vugt

- 14.00** **Make it or break it: DNA end processing at DNA breaks, telomeres and stalled replication forks**
Jacqueline Jacobs, *Netherlands Cancer Institute, Amsterdam*
- 14.15** **Dietary mutagens and intestinal cancer in Lynch Syndrome**
Emily Rayner, *Leiden University Medical Center*
- 14.30** **Coffee/Tea**

Session VII: Cancer Metabolism (3x)

Chairs: Jan vd Bossche, Jeroen Guikema

- 15.00** **The Warburg effect supports stem cell identity through epigenetic remodeling in colorectal tumors**
Nguyen T.B. Nguyen, *Center for Molecular Medicine (CMM), UMC Utrecht*
- 15.15** **Inhibition of mitochondrial metabolism constitutes a therapeutic vulnerability in IDH1/2-mutant Acute Myeloid Leukemia**

Dominique Sternadt, *University Medical Center Groningen*

15.30 **MLL (KMT2A)-Rearranged Acute Lymphoblastic Leukemias are Addicted to S-adenosyl Methionine (SAM): Implications for Therapy**

Trisha Tee, *Princess Máxima Center for Pediatric Oncology, Utrecht*

15.45 **Best presentation awards and closure**